Peter Fenici

TL;DR: Treatment with SGLT-2i versus other glucose-lowering drugs was associated with a lower risk of HHF and death, suggesting that the benefits seen with empagliflozin in a randomized trial may be a class effect applicable to a broad population of patients with type 2 diabetes mellitus in real-world practice.

TL;DR: In this article, a randomized trial demonstrated a lower risk of cardiovascular events with SGLT-2 inhibitors in patients with type 2 diabetes (T2D) at high risk of adverse events.

TL;DR: In a population of patients with type 2 diabetes and a broad cardiovascular risk profile, SGLT2 inhibitor use was associated with reduced cardiovascular disease and cardiovascular mortality compared with use of other glucose-lowering drugs.

TL;DR: How therapeutic inertia in the management of hyperglycaemia was measured was measured and its extent over the past decade was assessed to assess its extent.

TL;DR: In this large, international, real-world study of patients with type 2 diabetes, initiation of SGLT2 inhibitor therapy was associated with a slower rate of kidney function decline and lower risk of major kidney events compared with initiation of other glucose-lowering drugs.